Susquehanna International Group
CMPX icon

Susquehanna International Group’s Compass Therapeutics CMPX Stock Holding History

Susquehanna International Group’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$335K Buy
+63,400
New +$366K ﹤0.01% 10624
2025
Q2 		– Sell
-130,800
Closed -$249K – 12762
2025
Q1 		$249K Buy
+130,800
New +$348K ﹤0.01% 10488

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Susquehanna International Group's CMPX Position: Q1 2026 in Review

Susquehanna International Group increased its Compass Therapeutics (CMPX) stake by 251% in Q1 2026, buying an estimated $648K and bringing the position to 157,025 shares worth $831K. The position accounts for ﹤0.01% of the portfolio, ranked #8384.

Susquehanna International Group first reported a position in CMPX in Q3 2022 and has held it in 13 quarters since. The position peaked at $2.56M in Q1 2023. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Susquehanna International Group held 157,025 shares of Compass Therapeutics worth $831K as of Q1 2026.
  • Susquehanna International Group bought 112,283 Compass Therapeutics shares in Q1 2026, an estimated $648K.
  • Compass Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8384 holding.
  • Susquehanna International Group first reported a position in Compass Therapeutics in Q3 2022 and has held it in 13 quarters since.
  • Susquehanna International Group's Compass Therapeutics position peaked at $2.56M in Q1 2023.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.